Changes in Beneficial Ownership · 4
ProKidney Corp.
PROKNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-05-28
- Issuer
- PROKIDNEY CORP.
- Issuer CIK
- 0001850270
- Trading symbol
- PROK
Reporting owner 1
- Name
- Lotvin Alan
- Reporting owner CIK
- 0001472795
- Relationship
- Director
- Address
- C/O PROKIDNEY CORP, 2000 FRONTIS PLAZA BLVD, SUITE 250, WINSTON SALEM, NC, 27103
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Director stock option (right to buy) | 1.81 | 2026-05-28 | A · Form 4 | 135,000[F1] | A | 0 | [F2] | 2036-05-28 | Class A Common Stock | 135,000 | 135,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
Signature 1
- Signed
- /s/ Todd Girolamo, attorney in fact
- Date
- 2026-05-29
Company context
ProKidney, a pioneer in the treatment of CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com.